THERAPY DOSSIER · th-2f760ba49176

S-methyl-L-thiocitrulline (SMTC)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Haemorrhage/shock
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00845169 ↗NAcompleted

The Role of Nitric Oxide Synthase Isoforms in the Cardiovascular Effects of Air Pollution (forearm vascular study)

Endothelial Dysfunction

Enrolment: 16 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24726981 ↗2014Reported benefit

Administration of S-methyl-L-thiocitrulline protects against brain injuries after intracerebral hemorrhage.

RatHaemorrhage/shockUnspecifiedSprague-Dawleyn = 27 rats in totalIntraperitoneal3 mg/kg in 0.9% saline3 hours after haemorrhage induction

Model: Autologous blood infusion of 30 or 50 microlitres into the striatum as a model of intracerebral haemorrhage

SMTC given 3 hours after haemorrhage reduced NADPH-diaphorase activity (p < 0.05), gelatinolytic enzyme activation (p < 0.01), loss of laminin (p < 0.01) and occludin (p < 0.05) staining, neuronal death and neurological deficits at 24 hours.

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…